Mapping the interactome of overexpressed RAF kinase inhibitor protein in a gastric cancer cell line by unknown
Gu et al. BMC Cancer 2013, 13:536
http://www.biomedcentral.com/1471-2407/13/536RESEARCH ARTICLE Open AccessMapping the interactome of overexpressed RAF
kinase inhibitor protein in a gastric cancer cell line
Huan Gu1, Xianquan Zhan2*, Guiying Zhang1*, Lu Yan1, William CS Cho3, Maoyu Li2, Ting Liu1 and Zhuchu Chen2Abstract
Background: Gastric cancer (GC) is a threat to human health with increasing incidence and mortality worldwide.
Down-regulation or absence of RAF kinase inhibitor protein (RKIP) was associated with the occurrence, differentiation,
invasion, and metastasis of GC. This study aims to investigate the molecular mechanisms and biological functions of
RKIP in the GC biology.
Methods: The fusion expression plasmid pcDNA3.1-RKIP-3xFLAG was transfected into SGC7901 cells, the RKIP fusion
proteins were purified with anti-flag M2 magnetic beads, and the RKIP-interacting proteins were identified with tandem
mass spectrometry (MS/MS), and were analyzed with bioinformatics tools. Western blot and co-immunoprecipitation
were used to confirm the interaction complex.
Results: A total of 72 RKIP-interacting proteins were identified by MS/MS. Those proteins play roles in enzyme
metabolism, molecular chaperoning, biological oxidation, cytoskeleton organization, signal transduction, and
enzymolysis. Three RKIP-interaction protein network diagrams were constructed with Michigan Molecular Interactions,
functional linage network, and Predictome analysis to address the molecular pathways of the functional activity of RKIP.
The MS/MS-characterized components of the existing interaction complex (RKIP, HSP90, 14-3-3ε, and keratin 8) were
confirmed by Western blot analysis and co-immunoprecipitation.
Conclusion: This study is the first discovery of the interaction of RKIP with HSP90, 14-3-3, and keratin. The present data
would provide insight into the molecular mechanisms of how RKIP inhibits the occurrence and development of GC.
Keywords: Affinity chromatography, Co-immunoprecipitation, Fusion protein expression, Gastric cancer, RAF kinase
inhibitor protein (RKIP), Tandem mass spectrometryBackground
The incidence of gastric cancer (GC) ranks fourth among
cancers in the world, and its incidence and mortality rank
second among malignant tumors of the digestive tract
[1,2]. A total of 750,000 patients die from GC each year in
the world, including 160,000 patients in China [1]. The
pathogenesis of GC still remains unclear. Early gastric
diagnosis, the prediction of relapse and metastasis, and
prognosis assessment are of importance for GC preven-
tion. Therefore, searching for new tumor markers and
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reproduction in any medium, provided the orOur previous laser-capture microdissection (LCM)-
based quantitative proteomics studies found that RAF
kinase inhibitor protein (RKIP) was significantly down-
regulated in the GC tissues compared with the normal
gastric mucosa tissues [3,4]. RKIP is a small (21 kDa),
highly conserved cytoplasmic protein, and is a member
of the phosphate ester acyl diethanolamine-binding pro-
tein family that participates in lipid metabolism and
phospholipid membrane formation [5]. RKIP is exten-
sively expressed in a variety of tissues and different cell
types with multiple physiological and pathological func-
tions [5]. The abnormal expression of RKIP plays an im-
portant role in the growth and differentiation process of
GC [6] with evidences that a positive correlation between
RKIP expression and the degree of differentiation of the
GC tissue and a negative correlation between RKIP expres-
sion and tumor infiltration depth, TNM staging, and lymphThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Overall scheme of the experiments used to identify
and analyze the proteins that interact with RKIP in the GC biology.
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Western blot analyses [3,4].
Moreover, many studies have demonstrated a negative
correlation between RKIP protein and the metastatic
ability of malignant tumors such as prostate cancer,
breast cancer, colon cancer, melanoma, and adenocarcin-
oma, as well as the potential anti-cancer activity of RKIP
protein, which would be a novel therapeutic target for
cancer [7-14]. Besides, RKIP protein can promote the
apoptosis of tumor cells. It was reported that after treat-
ment with chemotherapy drugs, breast cancer and pros-
tate cancer cells can induce RKIP protein expression and
cell apoptosis [15]. The decreased expression of RKIP in
breast cancer cells and prostate cancer cells inhibits
chemotherapy-induced apoptosis, whereas the restoration
of RKIP expression can increase the sensitivity of the
tumor cells to chemotherapy drugs [15]. The loss of abnor-
mally expressed RKIP functions increases the resistance of
cancer cells to chemotherapy, which causes the growth of
the tumor cells [12]. Therefore, the down-regulation or ab-
sence of RKIP expression plays an important role in the
development of tumors.
Study found that RKIP interacts with a number of dif-
ferent proteins and regulates multiple signaling pathways
[16,17]. However, the molecular mechanisms, biological
functions, and the interacted proteins of RKIP inhibiting
the occurrence and metastasis of GC remain unclear.
Targeted proteomics is an effective approach for investi-
gating the molecular mechanisms and biological func-
tions of a given protein that is associated with a disease.
Meanwhile, the 3xFLAG system coupled with highly
specific and sensitive anti-FLAG antibodies is an effect-
ive and optimized approach for detection of fusion protein
and its interacting proteins [18-20], and has success-
fully used to study the PPP1CC2-interacting proteins in
transgenic mouse embryonic stem cells [21], NLRC4 phos-
phorylation [22], BAP1-interacting proteins [23], HMGB1-
interacting proteins [24], FAT10-interacting proteins [25],
and CyaA-interacting proteins [26]. In this study, the tar-
geted proteomic strategy combined 3xFLAG-based affinity
purification and tandem mass spectrometry to isolate
and identify the RKIP-related proteins from the RKIP-
overexpressed SGC7901 GC cell line (Figure 1). This study
would provide insight into the molecular mechanisms of
how RKIP inhibits the occurrence and development of GC.
Methods
Instruments and software
IPGphor, Ettan DALT II System, Image-Scanner (maximum
resolution 9,600 × 9,600 dpi; Amersham Biosciences,
Stockholm, Sweden), electrospray ionization-quadrupole-
time of flight (ESI-Q-TOF) Mass Spectrometer (Micromass,
Manchester, UK), PDQuest system (Bio-Rad laboratories,
Hercules, CA), Mascot Distiller and Mascot DatabaseSearch engine, and Statistical Package For Social Science
(SPSS for windows, Version 17.0, Chicago, IL, USA)
were used.
Cell lines and plasmid
Human gastric carcinoma cells (SGC7901) were purchased
from the Laboratory for Cancer Research (Central South
University, China). SGC7901 cells were cultured with
RPMI1640 medium containing 10% fetal calf serum (Gibco
BRL, Grand Island, NY). The pCDNA3.1-RKIP-3xFLAG
plasmid, pcDNA3.1-3xFLAG plasmid, and pcDNA3.1-
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ogy Co., Ltd. A total of four experimental groups were
set up: SGC7901 cells tranfected with pcDNA3.1-RKIP-
3xFLAG plasmid (RKIP-3xFLAG group), SGC7901 cells
tranfected with pcDNA3.1-3xFLAG plasmid (3xFLAG
group), SGC7901 cells tranfected with pcDNA3.1-RKIP
plasmid (RKIP group), and SGC7901 cells (Blank group).
Transfection
SGC7901 cells were recovered, cultured for logarithmic
cell growth, then before transfection SGC7901 cells were
plated into 15-cm2 petri dishes. The cells were used for
transfection when the cell reached 90% confluency and
were assigned to either the RKIP-3xFLAG group (fusion
carrier group), the 3XFLAG group (blank carrier group),
RKIP group (which was used to validate whether 3xFLAG
affects the expression of RKIP), or the blank group.
Transfection was conducted according to the Lipofectami-
neTM2000 instructions for liposome transfection.
Western blot analysis of RKIP and fusion proteins
The expressions of RKIP proteins and RKIP-3xFLAG fu-
sion proteins were detected by Western blot analysis
after transfection. The procedure was performed as fol-
lows: the cells were collected from the flasks, washed
three times with cold PBS, and lysed (4°C, 30 min) in a
lysis buffer. The protein concentration was determined
with a protein assay kit (Bio-Rad laboratories). Protein
extracts (about 20 mg) were subjected to SDS–PAGE
with a 10% acrylamide gel. The gel-separated proteins
were transferred to PVDF membranes (Millipore Corpor-
ation, Bedford, MA), incubated with primary antibodies,
including anti-RKIP, anti-Flag, and anti-β-actin anti-
bodies (Santa Cruz biotechnology, Santa Cruz, CA), and
probed with secondary antibodies. The PVDF mem-
branes with protein-antibody complexes were washed
tree times with TBST buffer. The proteins on the PVDF
membranes were visualized with the enhanced chemilu-
minescence (ECL) detection system. Western blot analysis
was repeated at least three times.
Purification of RKIP fusion proteins
The proteins from the RKIP-3xFLAG group, 3xFLAG
group, and blank group were purified according to the
FLAG M2 magnetic beads manual procedures of protein
purification (each experimental step was conducted at
2–8°C), respectively. Briefly, an adequate amount of affinity
gel in a clean centrifuge tube was centrifuged (5,878 x g,
30 sec) and was allowed to precipitate (approximately
2 min). The supernatant was discarded and the precipitate
was washed twice with TBS solution that was equivalent to
20-fold volumes of the magnetic bead solution. The super-
natant was discarded, and the pellet was washed with
0.1 M glycine (pH 3.5) HCl (20 min). The protein samplesand affinity gel were mixed and incubated (overnight, 4°C).
The incubated mixture was centrifuged (4°C, 5,878 x g,
30 sec), and the supernatant was carefully removed. The
pellet was treated with a pre-chilled solution. The proteins
from each group were denatured in a boiling water bath
(3 min), centrifuged (2,296 x g, 30 sec), and stored at low
temperature (−80°C) for further analyses.MS/MS-identification of proteins
After 1D SDS-PAGE separation of the purified proteins
from three groups (RKIP-3xFLAG, 3xFLAG, and Blank),
respectively,the proteins that were contained in the gel
bands were digested with trypsin, and the tryptic peptide
mixture was analyzed with Micromass ESI-Q-TOF
MS/MS. The tryptic peptide samples were loaded onto a
pre-column (320 μm× 50 mm, 5 μm C18 silica beads;
Waters) to be concentrated and quickly desalted (30 l/min
flow-rate) through a Waters CapLC autosampler. The con-
centrated and desalted tryptic peptides were online eluted
to the reversed-phase column (75 μm×150 mm, 5 mm,
100 Å, LC Packing) at a flow-rate of 200 nl/min. MS/MS
spectra were acquired in a data-dependent mode in which
up to four precursor ions above an intensity threshold of
seven counts/second (cps) from each survey “scan” were
selected for MS/MS analysis. The nanospray parameters
were the following: a 3,000 V capillary voltage, a 45 V
cone voltage, an 80°C source temperature, and a 15-psi
collision gas back pressure. The MS/MS data were used
to search the identified proteins against the protein data-
base with the Mascot search engine. The search parame-
ters used were the following: homo sapiens as the current
species, a mass tolerance of +0.5 Da, an MS/MS tol-
erance of +0.3 Da, up to 1 missed cleavage site, fixed
carboxymethyl (cysteine) modification, variable oxidation
(methylation) modification, the Micromass PKL format,
and the ESI Q-TOF instrument. The proteins identified
from the blank-carrier control group and from the blank
control group were regarded as non-specific proteins, and
were removed from the protein list identified from the
pcDNA3.1-RKIP-3xFLAG test group to rule out the non-
specifically binding proteins of RKIP.Co-immunoprecipitation
A volume (1 ml) of extraction buffer that contained
1.5 mg of protein from cells was mixed with 5 μl of non-
immune rabbit serum and 50 μl of protein G-sepharose
4B beads was oscillated (40°C, 2 h) and centrifuged
(2,296 x g, 3 min) to eliminate the nonspecific binding of
proteins. After centrifugation, the supernatant was retained
and mixed with 20 μg of RKIP antibodies and 50 μL of
protein G-sepharose 4B beads (40°C, oscillation, 3 h). The
mixture was centrifuged (2,296 x g, 3 min). The beads were
retained and washed three times with TBST buffer. Non-
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used as controls.
Construction of the RKIP-interaction protein
network diagrams
VisANT 3.8.6 software (http://visant.bu.edu/) was used
to analyze and construct the RKIP-interaction protein
network diagrams. VisANT is an interactive software
platform that is to visualize, mine, analyze, and model bio-
logical networks. When VisANT was used in this study,
homo sapiens was selected for the current species param-
eter, and the Uniprot IDs of RKIP and of the 72 identified
proteins were entered into the search box. Three data-
bases, including Michigan Molecular Interactions (MiMI),
functional linage network, and Predictome, were chosen
to acquire the interaction network diagrams. The MiMI
tool was provided by the National Institute of Health’s
National Center for Integrative Biomedical Informatics.
The MiMI tool provides access to the knowledge and
data that have been merged and integrated from numer-
ous protein-interaction databases, and it augments the
information from many other biological sources. The
Predictome database is based on the implementation of
published computational methods and publicly available
data and can precisely predict the connections between
proteins; the associations are created using a variety of
techniques, both experimental (yeast two-hybrid, immuno-
coprecipitation, correlated expression) and computational
(gene fusion, chromosomal proximity, gene co-evolution).
For the constructed protein network diagrams, each
protein was located on a different level based on the
interaction between that protein and RKIP. The 1st
level neighbors were the directly interacting proteins,
the 2nd level neighbors are the secondary interacting
proteins, and the 3rd level neighbors were the tertiary
interacting proteins. The 1st and 2nd level neighbors
in the RKIP-interaction protein networks were consid-
ered to be the closely interacting proteins of RKIP be-
cause the interactions of RKIP with the 1st and 2nd
level neighbors were much closer than those with the
other level neighbors.Figure 2 The expression levels of RKIP in RKIP-3xFLAG, RKIP, and 3xF
the Western blot image (p < 0.05). The 3xFLAG did not affect the expressioValidation of RKIP-related proteins
Western blot analysis and co-immunoprecipitation were
used to validate the interactions of HSP90, 14-3-3ε, and
Keratin 8 with RKIP. The total protein from SGC7901
cells was precipitated in an appropriate lysis buffer con-
taining RKIP antibody. The immunoprecipitated pro-
teins were further analyzed by SDS-PAGE. Western blot
analysis was used to detect HSP90, 14-3-3ε, and keratin
8 with their corresponding antibodies in order to study
the target proteins’ interactions with RKIP. Non-immune
IgY antibodies replaced the RKIP antibodies as negative
controls (3×).
Statistical analysis
All experiment data were expressed as mean ± SE and
analyzed with Student’s t-test with a statistical signifi-
cance level of p < 0.05.
Results
Expression of RKIP protein in transfected cells
The expression level of RKIP protein in transfected cells
was determined by Western blot analysis. The intensity
of the Western blot images was analyzed with IPP 6.0
software and represented the relative amount of protein
expression. The Western blot analysis shows that the
RKIP expression levels of the RKIP-3xFLAG group and
of the RKIP group were significantly higher than those
of the 3xFLAG group (p < 0.05; Figure 2).
Purification of RKIP fusion proteins
After the affinity-magnetic bead purification, with anti-
flag M2 magnetic beads, of the total protein from the
cells, most of the protein sample was pre-separated by
1D-SDS-PAGE using a 10% acrylamide gel. The experi-
ment was repeated three times with the same test condi-
tions and parameter settings, and then the gel images
were obtained with clear backgrounds, high resolution,
and good reproducibility. A total of 14 RKIP interacting
protein bands were identified (Figure 3A).
Western blot analysis was used to test the remaining
protein samples. The results demonstrated that no cross-LAG groups. A. Western blot image. B. The intensity of the bands in
n of RKIP.
Figure 3 Separation of RKIP-interacting proteins with anti-flag
M2 magnetic beads and 1D SDS-PAGE. A. After the affinity
magnetic bead based purification, with anti-flag M2 magnetic beads,
of total protein from the cells, the protein sample was pre-separated
by 1D-SDS-PAGE using a 10% acrylamide gel. The clear channel proteins
(n = 14) were separated in the experimental group. B. Western blot
analysis to test RKIP-3xFLAG expression in different groups of affinity
purified cells. After the affinity magnetic bead based purification,
with anti-flag M2 magnetic beads, of total protein from the cells,
RKIP-3xFLAG expression was detected in only the RKIP-3xFLAG group,
whereas no RKIP-3xFLAG expression was detected in the 3xFLAG and
blank groups.
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groups occurred; three reproducible tests confirmed
the reliability (Figure 3B).
Identification of RKIP-related proteins
The RKIP-related proteins were separated with 1D-SDS-
PAGE and visualized with Coomassie brilliant blue R-
250. The proteins in the gel-bands were subjected to
in-gel trypsin digestion. The tryptic peptides were ana-
lyzed with ESI-Q-TOF MS/MS. The obtained MS/MS
data were used to identify the proteins with Mascot soft-
ware to search the Swiss-Prot or the NCBInr database;
this experiment was repeated three times. The proteins
that only appeared in the RKIP-3xFLAG group were
chosen to effectively rule out the non-specific proteins.
However, no proteins were identified by MS/MS in the
3xFLAG and blank groups, which is consistent with
the results of gel-image without any protein band in
the Figure 3. This confirmed that the identified proteins
from the pcDNA3.1-RKIP-3xFLAG group were the RKIP-
interacting proteins. A total of 72 proteins were MS/
MS-identified (Table 1; Additional file 1: Table S1). The
identified proteins belong to different functional cat-
egories (Figure 4; Table 1), including metabolic enzymes
(n = 13; 18%), molecular chaperones (n = 8; 11%), biologicaloxidation-related proteins (n = 2; 3%), signal transduction-
related proteins (n = 8; 11%), cytoskeleton-related pro-
teins (n = 16; 22%), protease-related proteins (n = 18;
25%), and others (n = 7; 10%). The same proteins (14-3-3,
keratin, filamin, tubulin, GSTP1, HSP90, DHX9, actin,
and vimentin) were consistently identified in three re-
peated experiments.
RKIP-interaction protein network diagrams and validation
of the RKIP-protein complex
VisANT software with three functional models (MiMI,
functional linkage network, and Predictome) was used to
search for interactions between RKIP and the 72 identi-
fied proteins, to construct the RKIP interaction network
diagram, and to define the levels of interaction between
the identified proteins and RKIP (Figure 5).
In the protein network diagram that was derived from
the database retrieval with MiMI, among the 72 RKIP-
related proteins, 16 proteins were classified as the 1st level
neighbors of RKIP, 19 proteins were classified as the 2nd
level neighbors of RKIP, 29 proteins were classified as the
3rd level neighbors of RKIP, and 8 proteins were found to
not interact with RKIP (Figure 5A, Table 2).
In the protein network diagram that was derived from
the database retrieval with the functional linage network,
among the 72 RKIP-related proteins, 41 proteins were
classified as the 1st level neighbors of RKIP, 21 proteins
were classified as the 2nd level neighbors of RKIP, and
10 proteins were classified as the 3rd level neighbors of
RKIP (Figure 5B, Table 2).
In the protein network diagram that was derived from
the database retrieval with Predictome, among the 72
RKIP-related proteins, 43 proteins were classified as the
1st level neighbors of RKIP, 16 proteins were classified as
the 2nd level neighbors of RKIP, 9 proteins were classified
as the 3rd level neighbors of RKIP, and 4 proteins were
found to not interact with RKIP (Figure 5C, Table 2).
Of the 72 RKIP-related proteins, only 35 proteins
closely interacted with RKIP, as determined from the
MiMI analysis. However, all 72 proteins had functional
relationships with RKIP with the functional linage net-
work and Predictome database analyses, and 69 proteins
were predicted to closely interact with RKIP. In all three
database analyses, 35 proteins were consistently found
to be closely related to RKIP, including HSP90, 14-3-
3ε, Keratin 8, IQGAP1, MYH9, CLH1, PLEC1, and EF2
(Table 2).
In our previous study, HSP90, 14-3-3ε, and keratin 8
were discovered to be significantly changed in the GC
tissues compared with in the normal gastric mucosa
tissues [3]. MiMI, functional linage network, and Predic-
tome were three independent software and databases.
Through the MiMI analysis, these proteins were classified
as 2nd level neighbors of RKIP; through the functional
Table 1 RKIP-related proteins identified with ESI-Q-TOF MS/MS






P53618 Coatomer subunit beta 108,241 89 3 Mediate biosynthetic protein transport
P14618 Pyruvate kinase isozymes M1/M2, isoform M2 58,470 604 40 Glycolytic enzyme
P00966 Argininosuccinate synthase 46,791 142 6 ATP binding
P00558 Phosphoglycerate kinase 1 44,992 102 3 Glycolytic enzyme
P08195 4F2 cell-surface antigen heavy chain,
isoform 2
68,180 56 2 Function of light chain amino-acid transporters
P06733 Alpha-enolase 47,481 517 25 Multifunctional enzyme
P04406 Glyceraldehyde-3-phosphate dehydrogenase 36,201 769 80 Glyceraldehyde-3-phosphate dehydrogenase
and nitrosylase activities
P07195 L-lactate dehydrogenase B chain 36,900 74 5 L-lactate dehydrogenase activity
P00338 L-lactate dehydrogenase A chain, isoform 1 36,950 43 4 L-lactate dehydrogenase activity
P40926 Malate dehydrogenase, mitochondrial 35,937 49 3 L-malate dehydrogenase activity
P46940 Ras GTPase-activating-like protein IQGAP1 189,761 55 3 Promote neurite outgrowth
P68104 Elongation factor 1-alpha 1 50,451 190 11 Protein biosynthesis
P02786 Transferrin receptor protein 1 85,274 74 3 Molecular transducer activity
II. Molecular chaperone
P14625 Endoplasmin 92,696 192 18 Molecular chaperone ATPase activity
P07900 Heat shock protein HSP 90-alpha, isoform 2 85,006 280 24 Stress related, chaperone
P08238 Heat shock protein HSP 90-beta 83,554 276 25 Stress related, chaperone
P11142 Heat shock cognate 71 kDa protein,
isoform 1
71,082 398 16 Stress related, chaperone
P38646 Stress-70 protein, mitochondrial 73,920 253 7 Related with cellular proliferation and aging
P10809 60 kDa heat shock protein, mitochondrial 61,187 723 22 Stress related, chaperone
P53992 Protein transport protein Sec24C 119,789 61 5 Component of the COPII coat
P50454 Serpin H1 46,525 133 3 Chaperone in the biosynthetic pathway of
collagen
III. Biological oxidation-related proteins
O00299 Chloride intracellular channel protein 1 27,248 78 3 Voltage-gated chloride channel activity,
redox-regulated
Q06830 Peroxiredoxin-1 22,324 51 7 Redox regulation
IV. Signal transduction
O43390 Heterogeneous nuclear ribonucleoprotein R, isoform 1 71,184 63 2 mRNA processing, ribonucleoprotein
P52597 Heterogeneous nuclear ribonucleoprotein F 45,985 110 2 mRNA processing, ribonucleoprotein
P04083 Annexin A1 38,918 454 24 Signal transduction, calcium ion binding
P12429 Annexin A3 36,524 53 4 Signal transduction, calcium ion binding
P08758 Annexin A5 35,971 50 10 Signal transduction, calcium ion binding
P62258 14-3-3 protein epsilon 29,326 136 6 Anti-apoptosis, signal transduction,
transcription factor binding
P23396 40S ribosomal protein S3 26,842 122 9 NF-KappaB binding
Q99623 Prohibitin-2 33,276 38 5 Mediate transcriptional repression
V. Cytoskeleton-related proteins
O75369 Filamin-B, isoform 1 280,157 91 1 Connects cell membrane constituents to
the actin cytoskeleton
P21333 Filamin-A, isoform 2 283,301 91 3 Actin binding
P18206 Vinculin, isoform 1 124,292 668 30 Actin filament-binding protein
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Table 1 RKIP-related proteins identified with ESI-Q-TOF MS/MS (Continued)
P04264 Keratin, type II cytoskeletal 1 66,170 89 4 Cytoskeleton of Intermediate filaments
P05787 Keratin, type II cytoskeletal 8 53,671 156 11 Cytoskeleton of Intermediate filaments
Q04695 Keratin, type I cytoskeletal 17 48,361 221 10 Cytoskeleton of Intermediate filaments
P05783 Keratin, type I cytoskeletal 18 48,029 547 35 Cytoskeleton of Intermediate filaments
Q15149 Plectin-1, isoform 1 533,462 73 11 Actin binding
P35579 Myosin-9, isoform 1 227,646 62 10 Play a role in cytokinesis, secretion
P68371 Tubulin beta-2C chain 50,255 245 19 The major constituent of microtubules
P07437 Tubulin beta chain 50,095 309 25 The major constituent of microtubules
P60709 Actin, cytoplasmic 1 42,058 617 36 Involved in various types of cell motility
P52907 F-actin-capping protein subunit alpha-1 33,073 61 3 Actin binding
P04075 Fructose-bisphosphate aldolase A 39,851 141 7 Actin binding
P08670 Vimentin 53,619 574 17 Cell motility, structural constituent of
cytoskeleton
Q9NYL9 Tropomodulin-3 39,741 85 9 Actin binding
VI. Protease-related proteins
P53396 ATP-citrate synthase 121,674 225 7 Enzyme regulator activity
P55072 Transitional endoplasmic reticulum ATPase 89,950 42 3 Necessary for the formation of transitional
endoplasmic reticulum
Q08J23 tRNA (cytosine-5-)-methyl transferase NSUN2 87,214 78 2 RNA methyltransferase
P06576 ATP synthase subunit alpha, mitochondrial 59,828 158 9 Mitochondrial membrane ATP synthase
P60842 Eukaryotic initiation factor 4A-I 46,357 169 7 ATP-dependent RNA helicase
P55786 Puromycin-sensitive aminopeptidase 103,895 117 3 Involved in proteolytic events essential for
cell growth and viability
P50395 Rab GDP dissociation inhibitor beta 51,095 78 3 Rad GDP-dissociation inhibitor activity
P42330 Aldo-keto reductase family 1 member C3 37,229 35 2 Aldo-keto reductase activity
P63244 Guanine nucleotide-binding protein
subunit beta-2-like 1
35,511 112 3 Up-regulation of the activity of kinases
P61289 Proteasome activator complex subunit 3,
isoform 1
29,602 77 2 Endopeptidase activator activity
P09211 Glutathione S-transferase P 23,569 56 30 Glutathione transferase activity
P13639 Elongation factor 2 96,246 240 9 Catalyzes the GTP-dependent ribosomal
translocation
Q15029 116 kDa U5 small nuclear ribonucleoprotein
component
110,336 130 6 Component of the U5 snRNP complex
P10696 Alkaline phosphatase, placental-like 57,626 140 8 Alkaline phosphatase activity
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2,
isoform 1
27,134 108 3 Mitochondrial tRNA maturation
Q08211 ATP-dependent RNA helicase A 142,181 264 12 Transcriptional activator
P41252 Isoleucyl-tRNA synthetase, cytoplasmic 145,718 94 9 Isoleucine-tRNA ligase activity
P26640 Valyl-tRNA synthetase 141,642 78 4 ATP binding
VII. Others
Q13263 Transcription intermediary factor 1-beta,
isoform 1
90,261 59 3 Nuclear corepressor for KRAB
domain-containing zinc finger proteins
Q14974 Importin subunit beta-1 98,420 84 2 Protein domain specific binding
P26641 Elongation factor 1-gamma 50,429 65 2 Unknown
P21796 Voltage-dependent anion-selective channel
protein 1
30,868 78 3 Voltage-gated anion channel activity
P61026 Ras-related protein Rab-1A, isoform 1 22,755 45 1 Involved in vesicular trafficking and
neurotransmitter release.
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Table 1 RKIP-related proteins identified with ESI-Q-TOF MS/MS (Continued)
Q00610 Clathrin heavy chain 1, isoform 1 193,620 36 3 The polyhedral coat of coated pits and vesicles
Q14683 Structural maintenance of chromosomes
protein 1A
143,771 221 6 Involved in chromosome cohesion
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functionally related to RKIP; and through the Predictome
analysis, they were found to directly interact with RKIP.
Those three proteins were further verified by Western blot
analysis in combination with co-immunoprecipitation; the
results confirmed the proteins’ interactions with RKIP. The
results show that the protein expressions of the MS/MS-
characterized HSP90, 14-3-3ε, and keratin 8 (Additional
file 2: Table S2) were detected in the RKIP immune com-
plex (Figure 6) and they were not detected when the RKIP
antibody was replaced by IgY antibody.Discussion
The RKIP that was found to be down-regulated or ab-
sent in GC in our previous study [3], which is associ-
ated with the occurrence, differentiation, invasion, and
metastasis of GC. Recent studies further found that RKIP
can prevent the phosphorylation and activation of MEK
that is mediated by the RAF-1 and MAPK signaling path-
ways [9]. RKIP can also participate in the regulation and
control of the G protein coupling receptor signaling path-
way and the NF-kB signaling pathway [16,27]. These
signaling pathways play important roles in cell growth,
proliferation, differentiation, and tumorigenesis processes,
which strongly suggests that abnormal expression of RKIP
is involved in tumorigenesis. Our previous study also
revealed that the abnormal expression of RKIP plays
an important role in the growth and differentiation process
of GC.Figure 4 Functional categories of RKIP-interacting proteins
(n = 72). I. Metabolic enzymes (n = 13; 18%); II. Molecular chaperones
(n = 8; 11%); III. Biological oxidation-related proteins (n = 2; 3%); IV. Signal
transduction-related proteins (n = 8; 11%); V. Cytoskeleton-related
proteins (n = 16; 22%); VI. Protease-related proteins (n = 18; 25%); and VII.
Others (n = 7; 10%).Among numerous signaling pathways, the MAPK path-
way plays a crucial role in inflammatory signal trans-
duction, apoptosis, and tumor cell proliferation, and it
controls a variety of internal metabolic process. Extracel-
lular signal-regulated kinase (ERK) is a member of the
MAPK family. Its RAS/RAF/MEK/ERK signal transmis-
sion pathway is the core of the signal network, which is
involved in the regulation of cell growth, development,
and division [9,17,28].
RKIP can prevent the phosphorylation and activation of
MEK that is mediated by RAF-1; thus RKIP can also influ-
ence the MAPK signaling pathway by combining with its
interacting proteins. Therefore, we aim to study the RKIP-
interacting proteins in GC and the action mechanism of
the RAF/MEK/ERK signaling pathways which are influ-
enced by RKIP in this paper.
Proteomics in combination with fusion protein expres-
sion is the first approach to characterize RKIP-interacting
proteins. A total of 72 RKIP-related proteins were identi-
fied in the human gastric carcinoma cell line SGC7901.
The identified proteins belong to different functional cat-
egories, including those of metabolic enzymes, molecular
chaperones, biological oxidation-related proteins, signal
transduction-related proteins, cytoskeleton-related pro-
teins, protease-related proteins, and others. Among those
72 proteins, only 35 proteins were found through the
MiMI analysis to have existing interactions with RKIP;
however, through the functional linage network and the
Predictome database analyses, each of the 72 proteins was
found to be functionally related to RKIP, and 69 of the
proteins were found to closely interact with RKIP.
Studies have demonstrated that some of the 72 related
proteins, including MYH9, IQGAP1, annexin A1, vimen-
tin, and GSTP1, might play an important role in the oc-
currence, differentiation, invasion, and metastasis of GC.
The protein MYH9 functions in cytokinesis, cell motility,
and the maintenance of cell shape. Many studies suggest
that MYH9/NMHC-IIA plays a key role in tumor cell inva-
sive behavior; and a recent study shows that the inhibition
of MYH9/NMHC-IIA expression can inhibit the metasta-
sis of GC cells [29]. IQGAP1 was discovered to be upregu-
lated in GC, and its absence corresponds to a good clinical
prognosis [30]. The loss of annexin A1 expression has been
significantly associated with advanced stage lymph node
metastasis, an advanced disease stage, and poor histological
differentiation. The ANXA1 expression decreased signifi-
cantly as GC progressed and metastasized; this result sug-
gests the importance of ANXA1 as a negative biomarker
Figure 5 The RKIP-interaction protein network diagrams. Each protein network diagram was derived from the database retrieval with MiMI
(A), the functional linage network (B), and Predictome (C), respectively.
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demonstrated that the expression of vimentin was signifi-
cantly upregulated in GC tissue and that the elevated
vimentin expression was strongly correlated with lymph
node metastasis, lymphatic invasion, perineural invasion,
and pathological staging [32]. A recent study found that
GSTP1 mRNA and protein were present in drug resistant
gastric cells (including SGC7901 cells) and that the down-
regulated expression of GSTP1 was related to somatic pro-
moter hypermethylation and impaired ERK signaling in
GC cell lines [33].
HSP90 and 14-3-3 were found to be significantly chan-
ged in the GC tissues compared with in the normal gastric
mucosa tissues in our previous study [3]. In this study,
HSP90 and 14-3-3 were identified as 2nd level neighbors
of RKIP by the MiMI analysis (Figure 5A), as directly func-
tionally related to RKIP by the functional linage network
analysis (Figure 5B), and as likely to directly interact with
RKIP by the Predictome analysis (Figure 5C). The in-
teractions of RKIP with HSP90 and 14-3-3 proteinswere verified by Western blot analysis in combination
with co-immunoprecipitation (Figure 6). HSP90 and 14-
3-3 proteins also play an important role in the RAF/
MEK/ERK signaling pathways [34,35].
The heat shock protein 90 family is a group of highly
conserved proteins and expressed in all eukaryotic cells.
HSP90 is over-expressed in a variety of tumor cells. Liu
et al. have confirmed that HSP90 is also over-expressed
in SGC7901 GC cells [36]. In recent years, studies have
confirmed that heat shock protein family members such
as HSP90 may directly affect the anti-apoptotic mecha-
nisms of cells, and that, because of HSP specific func-
tions, HSP90 plays an important role in the regulation of
the cell’s anti-apoptotic reaction. In the RAF/MEK/ERK
signaling pathways, the vital RAF-1 and MEK kinases
have been found to be substrate proteins of HSP90. Ex-
periments show that HSP90 is important for the regula-
tion of RAF-1 protein activity, intracellular positioning,
and stability. The use of HSP90 blockers to prevent the
interaction of HSP90 and RAF-1 can lead to a quick
Table 2 The levels of interaction between the identified proteins and RKIP that located in the RKIP-interaction protein
network diagrams (Figure 5), analyzed with the VisANT 3.8.6 protein-network analysis package
UniProt ID Protein name MiMI Functional linage network Predictome
P46940 Ras GTPase-activating-like protein IQGAP1 1st 1st 1st
P08238* Heat shock protein HSP 90-beta 2nd 1st 1st
Q14974 Importin subunit beta-1 1st 2nd 1st
P11142 Heat shock cognate 71 kDa protein 1st 1st 2nd
P14618 Pyruvate kinase isozymes M1/M2 1st 1st 1st
P06576 ATP synthase subunit alpha, mitochondrial 1st 1st 1st
P07437 Tubulin beta chain 1st 3rd 1st
P68104 Elongation factor 1-alpha 1 1st 1st 1st
P60709 Actin, cytoplasmic 1 1st 1st 2nd
P05783 Keratin, type I cytoskeletal 18 1st 2nd 2nd
Q15149 Plectin 1st 2nd 1st
P21796 Voltage-dependent anion-selective channel protein 1 1st 1st 1st
P23396 40S ribosomal protein S3 1st 2nd 1st
P63244 Guanine nucleotide-binding protein subunit beta-2-like 1 1st 2nd 2nd
Q00610 Clathrin heavy chain 1 1st 1st 1st
P41252 Isoleucyl-tRNA synthetase, cytoplasmic 1st 1st 1st
P60842 Eukaryotic initiation factor 4A-I 2nd 1st 1st
P04075 Fructose-bisphosphate aldolase A 2nd 1st 2nd
P52907 F-actin-capping protein subunit alpha-1 2nd 1st 1st
P04406 Glyceraldehyde-3-phosphate dehydrogenase 2nd 3rd 2nd
P07195 L-lactate dehydrogenase B chain 2nd 1st 2nd
P04083 Annexin A1 2nd 1st 2nd
P00338 L-lactate dehydrogenase A chain 2nd 1st 3rd
P62258* 14-3-3 protein epsilon 2nd 1st 1st
P26640 Valyl-tRNA synthetase 2nd 1st 2nd
P08670 Vimentin 2nd 1st 2nd
P35579 Myosin-9 2nd 1st 1st
P18206 Vinculin 2nd 3rd 2nd
P13639 Elongation factor 2 2nd 1st 1st
P07900 Heat shock protein HSP 90-alpha 2nd 1st 1st
P38646 Stress-70 protein, mitochondrial 2nd 1st 2nd
P10809 60 kDa heat shock protein, mitochondrial 2nd 1st 1st
P05787* Keratin, type II cytoskeletal 8 2nd 2nd 1st
P06733 Alpha-enolase 2nd 3rd 1st
P26641 Elongation factor 1-gamma 2nd 2nd 1st
Q15029 small nuclear ribonucleoprotein component 3rd 1st 1st
P08195 4 F2 cell-surface antigen heavy chain 3rd 2nd 2nd
P53396 ATP-citrate synthase 3rd 1st 1st
O75369 Filamin-B 3rd 2nd 1st
P53992 Protein transport protein Sec24C 3rd 2nd 1st
P53618 Coatomer subunit beta 3rd 3rd 3rd
P14625 Endoplasmin 3rd 1st 1st
Q13263 Transcription intermediary factor 1-beta 3rd 2nd 1st
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Table 2 The levels of interaction between the identified proteins and RKIP that located in the RKIP-interaction protein
network diagrams (Figure 5), analyzed with the VisANT 3.8.6 protein-network analysis package (Continued)
P02786 Transferrin receptor protein 1 3rd 3rd 1st
P55072 Transitional endoplasmic reticulum ATPase 3rd 1st 1st
O43390 Heterogeneous nuclear ribonucleoprotein R 3rd 2nd 3rd
P68371 Tubulin beta-2C chain 3rd 2nd 1st
P50454 Serpin H1 3rd 1st 1st
P00558 Phosphoglycerate kinase 1 3rd 1st 1st
P50395 Rab GDP dissociation inhibitor beta 3rd 1st 2nd
P40926 Malate dehydrogenase, mitochondrial 3rd 2nd 1st
Q99623 Prohibitin-2 3rd 2nd 3rd
P12429 Annexin A3 3rd 1st 3rd
P08758 Annexin A5 3rd 1st 3rd
O00299 Chloride intracellular channel protein 1 3rd 2nd 1st
P61289 Proteasome activator complex subunit 3 3rd 1st 1st
P09211 Glutathione S-transferase P 3rd 3rd 1st
Q06830 Peroxiredoxin-1 3rd 2nd 1st
P61026 Ras-related protein Rab-10 3rd 3rd 3rd
Q99714 3-hydroxyacyl-CoA dehydrogenase type-2 3rd 3rd 1st
Q08211 ATP-dependent RNA helicase A 3rd 1st 1st
Q14683 Structural maintenance of chromosomes protein 1A 3rd 1st 1st
P04264 Keratin, type II cytoskeletal 1 3rd 1st 1st
Q9NYL9 Tropomodulin-3 3rd 3rd N/A
P21333 Filamin-A N/A 3rd 3rd
P55786 Puromycin-sensitive aminopeptidase N/A 2nd 1st
P52597 Heterogeneous nuclear ribonucleoprotein F N/A 1st 1st
Q04695 Keratin, type I cytoskeletal 17 N/A 2nd 2nd
P42330 Aldo-keto reductase family 1 member C3 N/A 1st 3rd
Q08J23 tRNA (cytosine-5-)-methyltransferase NSUN2 N/A 2nd N/A
P00966 Argininosuccinate synthase N/A 1st N/A
P10696 Alkaline phosphatase, placental-like N/A 1st N/A
Note: 1st means that the protein was located as the 1st level neighbors of RKIP; 2nd means that the protein was located as the 2nd level neighbors of RKIP; 3rd
means that the protein was located as the 3rd level neighbors of RKIP; and N/A means no interaction of RKIP with those proteins or the level of their interaction
was > the 3rd level. *(bold font) means the validated proteins that interacted with RKIP.
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stream MAPK activation, and induce apoptosis [34]. As
the previous studies have proven, HSP90 protein plays
an important role in the activation of the RAF/MEK/
ERK signaling pathways.
The 14-3-3 signaling proteins are a group of multi-
functional eukaryotic proteins that are highly conserved
and widely distributed. Some subtypes of 14-3-3 were
found in GC cell lines with high expression [37]. The
14-3-3 protein, in partnership with cancer gene or
proto-oncogene products, participates in cellular signal
transduction, plays a role in RAF/RAS/MAPK signaling,
directly affects the signal transmission related to phospho-
lipid activity and Ca2+, and is involved in T cell activationand cell apoptosis [10,38]. Studies have confirmed that
in the RAS/RAF/ERK/MEK signal transduction pathways,
the combination of 14-3-3 and RAF multiple sites were
the collaborative factor of RAF-1 and RAS. Additionally,
RAF-1 was transferred to the cell membrane by 14-3-3,
fixed in cell membrane by RAS, and then activated by
14-3-3. Therefore, 14-3-3 is the enzyme downstream of
RAS, in the MAPK pathway, with which RAF-1 inter-
acts [39,40]. Protein 14-3-3 plays a major role in main-
taining the stability of the RAS/RAF-1 complex and in
forming membrane sites. The involvement of 14-3-3
protein in the regulation of the RAF/MEK/ERK sig-
naling pathways has been reported [35]. Current re-
search suggests that 14-3-3σ, a member of the 14-3-3
Figure 6 The validation of RKIP-interaction proteins with
immunoprecipitation and Western blot analysis. The proteins
were immunoprecipitated, with RKIP antibody, from the total protein
extracts of SGC7901 cells and detected by Western blot analysis with
antibodies against HSP90, 14-3-3ε, and keratin 8. Non-immune IgY
antibodies were used to replace RKIP antibodies as negative
controls (3×).
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http://www.biomedcentral.com/1471-2407/13/536protein family, has tumor suppressor activity, while other
members of the 14-3-3 protein family have tumor promo-
tion activity. In our initial proteomic studies, the 14-3-3
protein that was found to be an RKIP-interacting protein
was 14-3-3ε. The overexpression of 14-3-3ε in vitro can
limitedly prompt the abnormal growth of renal tumor cells
[41]; and the cleavage and translocation of 14-3-3 epsilon is
significantly associated with the inhibition of colon cancer
cell proliferation [42]. Further study on the function of
14-3-3ε in the tumor signaling pathway would be warranted.Specificity of identified RKIP-interacting proteins
Specificity is a key issue in this study. In order to rule out
the nonspecific bound proteins, three experiment groups
were designed as pcDNA3.1-RKIP-3xFLAG, pcDNA3.1-
3xFLAG (blank-carrier) control group, and the blank
control group. The targets in this study are RKIP and its
interacting proteins. The blank-carrier control pcDNA3.1-
3xFLAG without RKIP fusion is a good, effective, and com-
parable control because the relative literature [18-26] has
been reported that 3xFLAG coupled its specifically effect-
ive antibodies is an efficient and high-performance system
to purify flag-tagged protein and its interacting partners. In
addition, the small size of the FLAG peptide tag is not
likely to obscure other epitopes, domains, or alter function,
secretion, or transport of the fusion protein, and affect the
interaction of the fusion protein with its partners [18].
Meanwhile, the previous quantitative proteomics studies
discovered that both of 14-3-3 protein and RKIP were dif-
ferentially expressed proteins in gastric carcinoma tissues
[3]; however, this 3XFLAG peptide tag experiment con-
firmed the interaction of RKIP with 14-3-3 protein.Conclusions
In summary, the targeted RKIP-interacting proteins were
analyzed with proteomic methods to address the mo-
lecular mechanisms and biological roles of RKIP in GC.
A total of 72 RKIP-related proteins were identified. All
of these 72 proteins were directly or indirectly related to
RKIP. Three RKIP-interaction protein network diagrams
were constructed with MiMI, the functional linage net-
work, and Predictome to address the molecular pathways
of the functional activities of RKIP. The interactions of
RKIP with HSP90, 14-3-3 protein, and keratin were veri-
fied by co-immunoprecipitation and Western blot ana-
lyses. Studies on HSP90 and 14-3-3 proteins in the RAS/
RAF/MEK/ERK signaling pathways have been reported
[34,35]. Those two proteins (HSP90 and 14-3-3ε) have
close relationships with this signal pathway and with the
transferring and activation of RAF-1. HSP90 and 14-3-3ε
were also associated with the growth and differentiation
process of GC. Because these two specific proteins are in-
volved in the mechanisms by which RKIP inhibits GC de-
velopment, HSP90 and 14-3-3ε proteins can consider as
early-stage biomarkers and targets for therapeutic strat-
egies to treat GC.
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